NURS 6630 Approaches To Treatment Of
Psychopathology MIDTERM EXAM
Questions and Answers
• Question 1
1 out of 1 point
When an unstable patient asks
... [Show More] why it is necessary to add
medications to his current regimen, the PMHNP’s best response
would be:
Selected C.
Answer: “Many psychiatric illnesses involve several dys-functioning neurotransmitter
systems in the brain. Often, a single medication may only effect one or two of the
dys-functioning systems. The addition of another medication can work with the
current medication in stabilizing multiple neurotransmitter systems and help to
alleviate your symptoms.”
• Question 2
out of 1 points
The PMHNP is meeting with a new mother who would like to begin
taking medication again to treat her bipolar depression; she is
breastfeeding her 2-month-old daughter. The PMHNP recognizes
that which of the following medications is contraindicated for this
patient?
Selected
Answer:
C.
Lithium
(Lithobid)
• Question 3
0 out of 1 points
Mr. Gordon is a middle-aged client who was started on antidepressant
monotherapy for depression. After beginning this medication, the PMHNP
noticed that this client seemed to swing into a hypomanic episode. What can
the PMHNP infer from this behavior change?
Selected
Answer:
A.
This client may have Bipolar III disorder
• Question 4
1 out of 1 points
A patient presents with frequent episodes of mania. Which statement
describes an appropriate treatment approach for this patient?
Selected
Answer:
B.
“The patient could benefit from an
anticonvulsant.”
• Question 5
1 out of 1 points
The student inquires about antipsychotic medications. Which
response by the PMHNP describes the factors that contribute to
reduced risk of extrapyramidal symptoms (EPS) for patients who
take antipsychotics?
Selected
Answer:
B.
Those that are potent D2 antagonists with 5HT2A
antagonism properties
• Question 6
1 out of 1 points
After ordering flumazenil (Rumazicon) the PMHNP cautions the staff to monitor for
which possible effect?
Selected
Answer:
D.
All of the
above
• Question 7
1 out of 1 points
The PMHNP is caring for a patient who is taking antipsychotics
heard the psychiatrist tell the patient that the patient would be placed
on a different antipsychotic agent called an atypical antipsychotic.
What neurotransmitters will this new medication work on?
Selected
Answer:
A.
dopamine and serotonin
• Question 8
1 out of 1 points
While genes have potential to modify behavior, behavior can also modify
genes. How do genes impact this process?
Selected
Answer:
B.
Changes made to proteins lead to changes in
behavior.
• Question 9
1 out of 1 points
Mrs. Schwartzman is a 52-year-old client with schizophrenia and no
established history of depression. When meeting with the PMHNP, she
presents with apathy and withdrawn social behavior, and she reports a loss
of joy from enjoyable activities since starting her new medication. What does
the PMHNP infer from this encounter with the client?
Selected
Answer:
C.
The new medication is blocking D2 receptors in the mesolimbic
system
• Question 10
A nursing student is seeking clarification on the use of
1 out of 1 points
anticonvulsants to treat depression and is unclear about most effective
outcomes. Which of the following agents does the PMHNP convey as
having uncertain outcomes?
Selected
Answer:
B.
Gabapentin
(Neurontin)
• Question 11
1 out of 1 points
As it relates to G-protein linked receptors, what does the PMHNP
understand about medications that are used in practice?
Selected
Answer:
A.
Most medications that act on G-protein linked receptors
have antagonistic traits.
• Question 12
1 out of 1 points
A patient is seeking pharmacological treatment for smoking
cessation. Which drug class does the PMHNP prescribe to the
patient?
Selected
Answer:
D.
Varenicline
(Chantix)
• Question 13
1 out of 1 points
The PMHNP is caring for a patient with schizophrenia and is
considering a variety of treatment approaches. The PHMNP selects
a viable treatment that is consistent with the “dopamine hypothesis
of schizophrenia.” What action does the PMHNP anticipate this
treatment having on the patient?
Selected B.
Answer:
Hyperactivity in the mesolimbic dopamine pathway
mediates the positive symptoms of [Show Less]